Healthcare

ImpediMed (ASX:IPD) has expanded the potential application of its SOZO platform after receiving US Food and Drug Administration 510(k) clearance for sarcopenia risk assessment.

Healius Limited (ASX:HLS) delivered a mixed FY26 result, highlighting meaningful progress in its underlying operational recovery while also reflecting the financial challenges associated with its broaderBusinessreset. The company reported a significant improvement in underlying profitability, supported by stronger pathology margins, cost reduction initiatives and …

The company noted that appreciation of the Australian dollar against key trading currencies during the second half affected the translation of overseasEarningsinto reported results, with an estimated impact of approximately $5.0 million in revenue and $2.4 million in nEBITDA. Excluding this foreign exchange impact …

Medical imaging software company Pro Medicus (ASX:PME) continues strengthening its position in healthcare technology following an FY26 result that highlighted record revenue, strong profitability and significant contract momentum. The company provides imaging solutions to healthcare organisations, with its growth strategy centred on recurring revenue, …

Pathology services provider Australian Clinical Labs (ASX:ACL) continues focusing on improving operational performance following an FY26 result that highlighted stronger profitability, expanding margins and an increased dividend. The company provides diagnostic pathology services across Australia, with performance influenced by testing demand, cost management and …

Medical-device company Epiminder (ASX:EPI) continues progressing its implantable continuous electroencephalography (EEG) monitoring technology for epilepsy, with the company focused on advancing clinical adoption and commercial opportunities. The company’s growth strategy centres on the Minder system, a device designed to provide continuous monitoring for patients …

Small-cap company Nexsen (ASX:NXN) remains in focus as investors assess future developments, corporate strategy and potential growth opportunities. As a smaller ASX-listed company, Nexsen’s market activity can be influenced by sentiment, liquidity conditions and updates relating to its underlying business activities.